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Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183S178(HSCT). Outcomes with myelaoblative conditioning have
been surprisingly poor with almost 1/3 of patients suc-
cumbing to early transplant related mortality (TRM). Most of
the fatalities occur due to cardiopulmonary failure. Mortality
is higher than that in other immunodeﬁciency syndromes,
however the reasons for this increased toxicity are unclear.
We hypothesized that prolonged steroid exposure during
HLH therapy may cause the development of cardiac hyper-
trophy. Compromised cardiac reserve could contribute to
poor outcome because of the multiple physiological stressors
associated with transplant.
We reviewed the records of 11 consecutive children under-
going HSCT at our institution from January 2004- December
2012. The age at diagnosis ranged from birth to 60 (median
2.5) months and the age at HSCT from 6-70 (median 9)
months. 8/11 had identiﬁed genetic defects (5 perforin, 2
MUNC, 1 Griscelli). All 11 received pre-HSCT therapy with
etoposide, cyclosporin and dexamethasone. 10/11 were in
complete disease remission at the time of HSCT. Conditioning
was fully ablative in 9/11(Bu, Cy, VP, ATG) and reduced in-
tensity in 2 (Flu/campath). 6 received marrow as stem cell
source. Donors were matched sibling in 1, and unrelated
donor in 5. 5 received unrelated umbilical cord. All patients
except the sibling donor received methylprednisonole at 1-2
mg/kg/day as GVHD prophylaxis. 3 had acute GVHD and
received additional therapy with high dose (>2 mg/kg/day)
steroids.
Pre transplantation echocardiograms were accessible for 6
patients; none had evidence of LVH. Post transplantation
echocardiograms were reviewed for all patients. 7/11 (64%)
never evidenced LVH at any point post-HSCT. TRM in this
group was 3/7 (42%) due to multi-organ system failure
(MOSF) (2) and adenovirus infection (1). 4/11 patients (36%)
developed LVH 1 - 18weeks post-HSCT. TRMwas 100% in this
group, higher than thosewithout LVH (p¼0.58) and all due to
MOSF. Infectious agents were only identiﬁed in 1/4 (adeno /
EBV) and recurrent HLH in one.
In light of these ﬁndings, particular attention to cardiac status
in patients with HLH is highly recommended. Further inves-
tigation is needed to identify pre and post SCT factors
contributing to cardiac hypertrophy. This will allow both pre-
ventativemeasures to be developed and optimalmanagement
to be provided when these patients become critically ill.262
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Chromosome 7 deletions are adverse prognostic factors asso-
ciated with worse outcomes in patients with hematologicalmalignancies. However there are few outcome data for he-
matopoietic stem cell transplant (HSCT) in pediatric patients
with hematological malignancies and chromosome 7 de-
letions. We now describe the outcome in 40 patients with
chromosome 7 abnormalities (ALL, n¼13, AML, n¼11, MDS,
n¼14 and JMML, n¼2) who received an allogeneic HSCTat our
institution between 2001-2013. The median age at the time of
transplant was 9 years (range: 1-18 years). There were 23 pa-
tients with monosomy 7, 12 with 7q- and 5 with 7p-. At the
time of transplant, 16 of the 24 patients with acute leukemia
(ALL/AML) were in CR (9-CR1, 6-CR-2, 1-CR3) and 8/24 had
active disease (3with primary refractory disease, 5 in relapse).
All patients with ALL (13/13),10/11 patientswith AML and 1 /2
patients with JMML received chemotherapy prior to trans-
plant, while patients with MDS received no prior therapy. Pa-
tients received HSCT from MRD (10), MUD (17), MMUD (4) or
haploidentical donors (9). The median time to engraftment
was 19 days (95%CI: 17-20 days). With a median follow up of
857 days (range 5 -4099 days), the 3-year overall survival (OS)
and disease free survival (DFS) for the entire cohort was 60%
and 53%, respectively. The OS and DFS correlated with the
underlying diagnosis with MDS patients having better 3-year
OS andDFS (OS:MDS (77%), AML (36%), ALL (67%), JMML (50%)
and DFS: MDS (64%), AML (36%), ALL (58%), JMML (50%)
Outcome was not signiﬁcantly affected by the type of chro-
mosome 7 deletion (3-year OS: monosomy 7 (59%), 7q- (53%),
7p- (80%), p ¼ 0.528). Upon further subdivision by diagnosis,
patients with MDS that had associated monosomy 7 had
signiﬁcantly better OS compared to patients with AML and
monosomy 7 as well as ALL and monosomy 7 (p ¼ 0.014 and
p ¼ 0.029, respectively). Patients with MDS and associated
chromosome 7 deletions, in particular monosomy 7, may
achieve very good OS and DFS after HSCT. In contrast, patients
with AML do not fare as well after HSCT.263
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Dyskeratosis congenita is a rare inherited bone marrow
failure and cancer predisposition syndrome with multi-
system involvement. While allogeneic hematopoietic stem
cell transplant (HSCT) can cure the bone marrow failure,
reported survival is low, with patients suffering unusual
complications post HSCT. We describe the long term
outcome in 6 patients with mutation proven DC following an
allo-HSCT at our institution between 1997e2011. To our
knowledge this is the ﬁrst report to begin to correlate ge-
notype to phenotype post HSCT. The median age was 4 years
(range: 2e13). 4 patients had mutations in the TINF2 gene, 1
in DKC1 and 1 had a homozygous TERTmutation. 4/6 patients
received reduced intensity conditioning (RIC) regimens and
Age
(yrs)
Sex Mutation Complications post HSCT Survival
5 F TINF2 Pulmonary: Pulmonary ﬁbrosis
Renal: Hemolytic uremic syndrome,
CKD
Vascular: Venous malformations
Heme: Hypocellular marrow
Other DC related: Leukoplakia, nail
dystrophy, alopecia, lacrimal duct
stenosis, vaginal stenosis, osteoporosis,
femur fracture
Alive
4 F TINF2 Pulmonary: Pulmonary ﬁbrosis
GI: Massive GI bleeding, ascites
Renal: Hepatorenal syndrome
Heme/BMT: Hypocellular marrow
Other DC related: Lacrimal duct stenosis
Dead
5 M TINF2 GI: Massive GI bleeding, ascites
Heme/BMT: Hypocellular marrow, oral
GVHD
ID: Disseminated adenovirus
Alive
2 M TINF2 GI: Massive GI bleeding, intestinal
obstruction and perforation
Renal: Thrombotic microangiopathy,
AKI
Heme/BMT: Acute GVHD (gut,
liver,skin)
Other DC related: Urethral meatus
stenosis
ID: HHV6, C difﬁcile colitis
Dead
13 M DKC1 GI: Esophageal stricture Alive
3 M TERT Heme/BMT: Acute gut GVHD Alive
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tients received HSCT from MRDs (4) and MMUDs (2). 5/6
patients engrafted with the 1st HSCT. One patient had pri-
mary engraftment failure and was rescued with a 2nd HSCT
from the same donor using MAC. 3/6 six patients developed
GVHD (acute GVHD e 2, chronic extensive GVHD -1). 4/6
patients are alive (OS: 67%) with a median follow up of 1753
days (range: 92e5963). However, all 4 patients with TINF2
mutations suffered unusual multi-system complications
which developed late (4e5 years) after HSCT. The 2 patients
with DKC1 and TERT mutation had no such atypical compli-
cations and are doing well at last follow up. Recent reports
describe a more severe phenotype in patients with TINF2
mutations and the extra-hematopoietic manifestations that
continue after transplantation suggest that HSCT can have
only limited impact on the natural course of their disease and
on their long-term outcome. These patients require close
multi-disciplinary follow up after HSCT to ensure early
detection of complications. Future improvements could
focus on the use of less toxic RIC regimens, measurement of
biomarkers to predict complications and perhaps novel
therapies to correct the underlying telomere defect.264
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Allogeneic hematopoietic stem cell transplantation (HSCT)
from unrelated donors became a common practice during
the last years to rescue children and adolescents with high
risk acute lymphoblastic leukaemia (ALL) who lack an HLA
identical sibling donor (MSD). However, heterogeneous ap-
proaches in donor selection and transplantation methods
hamper the interpretation of available data. Therefore we
compared the inﬂuence of donor source under standardized
methods. Twenty-nine centres participated in the prospec-
tive trial to evaluate whether the results of HSCT from HLA
matched donors (MD) are comparable to those of HLA
identical siblings in patients with high risk ALL.
118 patients (age 0.5-18 years, med. 10.2) underwent MSD-
HSCT and 313 MD-HSCT. 218 pts were in ﬁrst and 213
beyond 1st remission. Unrelated donors were compatible
for at least 9/10 matches with allelic typing. GvHD-pro-
phylaxis consisted of CSA only after MSD-HSCT and of CSA/
MTX/ATG after MD-HSCT. Patients older than 2 years
received total body irradiation and etoposide as condi-
tioning regimen. The stem cell source was for 82% of the
MSD-group bone marrow (BM), 10% received peripheral
blood stem cells (PBSC) and some received cord blood (CB).
In the MD-cohort, 66% received BM, 28% PBSC and the
remaining CB or combinations.
Results: After a median follow up of 4.2 years, the 4-year
disease free survival (DFS) is 0.700.04, the overall survival
(OS) 0.770.04 after MSD-HSCT and after MD-HSCT DFS is
0.660.03, OS 0.730.03 (n.s.); 4-years relapse-incidence is
0.220.04 after MSD-HSCT and 0.230.02 after MD-HSCT
(n.s.). Non-relapse mortality at 4 years is 0.060.02 for MSD
and 0.100.02 for MD (p-value 0.228). In multivariate anal-
ysis the only signiﬁcant impact on OS and DFS was 1st
remission compared to 2nd or 3rd remission with a Hazard
ratio of 1.71. However, engraftment was signiﬁcantly better
after MSD-HSCT: the median day to reach ANC >1000/ml/
lymphocytes >100/ml/platelets >50.000/ml was 17/14/22 af-
ter MSD-HSCT and 22/23/32 after MD-HSCT (p < 0.001). This
resulted in signiﬁcant less severe infections (  grade 3 CTA
3.0) e18% vs. 40% (p < 0.01) and less severe pulmonary
complications: 10% vs. 19% (p ¼ 0.034).
